The next decade of Indian API manufacturing — what we plan to revolutionise from Anand
China-plus-one, PLI, the rise of complex generics, and the operating bets a small Indian API manufacturer has to place to be relevant in 2035.
Indian API manufacturing in 2026 sits at the most consequential inflection point of the past two decades. The China-plus-one supply chain shift is real and accelerating. The Production-Linked Incentive scheme for bulk drugs has changed the economics for new capacity. The next wave of innovator off-patent molecules — particularly complex generics, peptides and contrast media — is converging on Indian manufacturers in a way the previous wave did not. From our plant in Anand, I see five concrete shifts that will define which Indian API companies are still standing in 2035. Here is how we are planning around them.
Shift one — China-plus-one is now a buyer demand, not just a thesis
Three years ago, customers in Europe, Japan and North America talked about supplier-diversification away from China as a future risk-management exercise. Today they are asking for documented Indian alternates on every active programme. The decision criteria are no longer pricing alone — they explicitly weight regulatory posture, environmental compliance, supply continuity and audit history.
What this means for an Indian SME is a very different conversation. The customer who would not have audited a Tier-2 Anand manufacturer five years ago will now send a team for a one-week qualification visit. Capacity expansion decisions are being underwritten by these new customer commitments. Laksh's product roadmap over the next 24 months adds three new families that exist specifically because the customer asked for an Indian alternate — none of them were on our list two years ago.
Shift two — PLI is real, but the marginal benefit is to the disciplined operator
The Production-Linked Incentive scheme for bulk drugs has put roughly ₹6,940 crore on the table for KSMs, intermediates and APIs across multiple categories. The first headlines were about the big four or five awardees. The under-discussed story is what happened to the second tier — the dozens of smaller producers who took the framework seriously, met the capacity thresholds and quietly built audit-ready capacity over the past three years.
Our read at Laksh is that PLI's enduring impact is not in the cheques but in the operating discipline it forced. The capacity utilisation thresholds, the export milestones, the documentation requirements — these are the inputs that turn a job-shop into an exporter. The next phase of incentives, if it arrives, should narrow further toward complex APIs, specialty intermediates and biocatalysis. Operators who can absorb those incentives without breaking their compliance posture are the ones who will compound.
Shift three — complex generics is where the margin lives
The simple-molecule generic API business is mature, low-margin and structurally competitive. The growth segment over the next decade is complex generics — peptides, gadolinium-based contrast agents (we make Gadodiamide and Gadobutrol), high-potency APIs, sterile injectables, controlled-release intermediates, and chiral resolution chemistry for single-enantiomer drugs.
Each of these requires capability investment that small Indian manufacturers historically avoided. Containment, sterile suites, chiral chromatography, specialised reactor configurations. The good news is that the customer is willing to pay for the capability when it exists. Our plant in Anand is moving deliberately in this direction — not because complex chemistry is fashionable, but because it is the only category where Indian manufacturing can earn a real margin for the next decade.
Shift four — environmental compliance becomes a competitive moat
Gujarat Pollution Control Board enforcement has tightened materially over the past five years. The next five will tighten further — both at state level and through customer audit pressure on Scope-3 emissions. The Indian manufacturers who treated environmental compliance as a checkbox are now facing rebuilds. The ones who designed the effluent treatment plant, solvent recovery and emissions controls into the original blueprint have a structural cost advantage.
Our blueprint at Vithal Udyognagar was built to current standards a decade ago. We are now investing in solvent recovery efficiency, water recycling, and emission monitoring upgrades — not because we have to, but because the customer increasingly asks. Green-chemistry credentials have moved from nice-to-have to qualifying gate in five years.
Shift five — digital QC and electronic batch records arrive at Tier-2
The Big Pharma customers are moving aggressively to electronic batch records, real-time HPLC integration with QC databases, and audit-trail systems that no Tier-2 Indian manufacturer could afford five years ago. The cost curve has come down. The customer demand has gone up. The next three years will see the standard Indian regulated-API plant operate with the digital backbone that previously only the top-decile facilities had.
We are mid-way through that journey at Laksh. The QC laboratory is being instrumented for electronic batch records and integrated LIMS. The cost is meaningful for a company our size; the payback over five years is unambiguous in both audit performance and customer trust.
What we are planning to revolutionise — concretely
Five operating bets we are making, in priority order. One — expand our iodine derivatives portfolio with three new specialty molecules that no Indian competitor currently offers, targeted at imaging-agent and specialty-pharma customers globally. Two — add chiral chromatography capability to the QC lab to handle the next generation of single-enantiomer customer programmes. Three — convert two of our six reactor trains to multi-purpose containment-rated configurations for high-potency API work. Four — digitise QC and batch records end-to-end by the end of 2027. Five — invest in solvent-recovery and water-reuse upgrades that reduce the plant's environmental footprint by a measurable percentage and document it for customer audits.
None of these are revolutionary on their own. Together, they redefine what a Tier-2 Indian regulated-API manufacturer looks like at the end of the decade. That is the revolution — quiet, capital-disciplined, customer-led, and audit-driven. Not slogans. Operating reality.
What I'd tell another founder
If you are running an Indian API SME and you are reading the same macro signals, three pieces of advice. One — pick two complex chemistries to specialise in over the next five years. Generalist Tier-2 manufacturers will be squeezed; specialists will be sought. Two — invest in environmental compliance ahead of the next tightening, not in response to it. The cost of catching up is higher than the cost of staying ahead. Three — treat your first regulated international customer as the only marketing investment that matters. Audits cleared compound; pricing wars don't.
The next decade belongs to Indian API. It does not automatically belong to every Indian API manufacturer. The bets you place in the next 24 months determine which side of that line you sit on.
Got a question on what you've just read — or a project that touches one of the categories above? Write directly to the office.
First-generation Indian industrialist. Founder and Managing Director of Laksh Finechem — a WHO-GMP, FDA and ISO-certified manufacturer of APIs, iodine derivatives and specialty chemicals.